For Patients Our Science Our Team Join Us Contact Us

Patients first
people always

With patients as our guiding stars, Astria Therapeutics’ dedicated and passionate team is devoted to bringing life-changing therapies to patients and families impacted by HAE and rare and niche allergic and immunological diseases.

Why Astria

Our name comes from the Greek word for star, and at Astria, patients are the stars that guide our journey.

Their stories inspire us, their successes energize us, and their challenges give us purpose.

Our stars illuminate our work, creating an environment of transparency and openness that allows us to build trust with each other, our patient communities, shareholders, and all of our partners and collaborators.

For Patients

We at Astria listen to the voices of HAE patient communities to better understand their unmet needs, which guide all that we do.

We are charting a new path for HAE patients – one that envisions an opportunity for a better quality of life with a long-acting preventative therapy that has meaningful efficacy with infrequent dosing. We are not stopping there. Our goal is to develop therapeutics that bring meaningful changes to patients’ lives by pushing the boundaries of what is currently perceived as the standard of care for rare and niche diseases in allergy and immunology.

Subscribe to our Newsletter and Join our Community

Our Science

Our lead program, STAR-0215, is in preclinical development to treat Hereditary Angioedema (HAE), a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway.

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, designed to provide long-acting, effective attack prevention for HAE.
Learn how STAR-0215 aims to prevent attacks in HAE.

Current Development

We are developing STAR-0215 to be a long-acting monoclonal antibody inhibitor of plasma kallikrein.

Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling.

Future Development

We expect to file an Investigational New Drug application for STAR-0215 in mid-2022 and plan to initiate a Phase 1 clinical trial with initial results anticipated by year end 2022.

Reducing Burden

We are working to reduce the treatment burden for people living with HAE, whose current options for preventative therapy require frequent administration (daily, or up to every 4 weeks). We believe we can do better with STAR-0215.

Our goal is to provide the most patient-friendly preventative treatment option for people living with HAE. We are driven to change the way patients and their families live with HAE by allowing them to focus their time and energy on what matters most to them.

Preclinical Data

Preclinical data support the potential for STAR-0215 to transform the way people live with HAE by providing long-acting, effective protection from attacks. STAR-0215 has demonstrated high potency for plasma kallikrein in an in vitro functional assay and exhibits a long plasma half-life in non-human primates.

These data support our plans to develop STAR-0215 as an innovative HAE treatment to protect people with HAE from attacks with dosing once every 3 months or longer.

About HAE

Hereditary Angioedema (HAE) is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway.

Approximately one in every 10,000 – 50,000 people are diagnosed with HAE; an estimated 8,000 people are diagnosed in the U.S. Most cases of HAE are caused by insufficient levels of functional C1-inhibitor, a protein that regulates plasma kallikrein, a critical mediator of bradykinin and edema.

On-demand treatments for HAE can help decrease the severity of an attack as it is occurring, and preventative treatments, taken chronically, can reduce the chance that an attack will occur. However, substantial need remains for effective treatment options with less burdensome administration.

With STAR-0215, our goal is to provide an effective preventative treatment, dosed once every 3 months or longer, to decrease the burden of disease and the burden of treatment for people with HAE.

Our Team

Our passion for scientific discovery and innovation is driven by the compassion that we feel for the patient communities that we serve. At Astria, our guiding star is to benefit our patients, address their pain points, and improve their quality of life. Our compassion for patients also brings with it a natural sense of urgency, agility, and operational efficiency in all that we do.

Leadership

Jill C. Milne, Ph.D.

Co-Founder and
Chief Executive Officer

Read Bio >

Noah Clauser, CPA

Chief Financial Officer

Read Bio >

Andrew A. Komjathy

Chief Commercial Officer

Read Bio >

Andrew Nichols, Ph.D.

Chief Scientific Officer

Read Bio >

Ben Harshbarger, J.D.

Chief Legal Officer

Read Bio >

Andrea Matthews

Senior Vice President,
Corporate Affairs

Read Bio >

Keri McGrail

Senior Vice President,
Human Resources

Read Bio >

Board of Directors

Join Our Team

We are seeking talented team members who are committed to our mission of bringing hope with life-changing therapies to patients and their families.

Our vision is a world where science, passion, and compassion create better todays and more tomorrows.

The values we hold true to us are:

Patients First

Integrity

Excellence

Impact

People Always

We understand that the best work is performed by those who are engaged in their job, and we foster an environment that is supportive, hard-working, and fun.

If you are interested in exploring employment opportunities at Astria, please send your cover letter and resume to careers@astriatx.com.

We are proud to be an Equal Opportunity Employer.

Current Openings:

Contact Us

For Investor Inquiries:

Andrea Matthews
investors@astriatx.com
617-349-1971

For Media Inquiries:

Elizabeth Higgins
media@astriatx.com

For General Inquiries:

info@astriatx.com

Social:

Astria TX on Facebook Astria TX on Twitter Astria TX on LinkedIn Astria TX on Instagram

Find Us:

100 High Street, 28th Floor | Boston, MA 02110 | P: 617-349-1971 | F: 617-273-2637